Thesis (doctoral)--Ludwig Maximilians-Universität zu München, 1979.

Thesis (Ph. D.)--University of Washington, 2004. / Vita. Includes bibliographical references (leaves 138-150).

La Chimiothérapie IntraPéritonnéale (CIP) est utilisée couramment pour traiter le cancer colorectal métastatique. Cependant il n'existe pas de protocole standardisé.Le but de ce projet a été de modéliser cette chimiothérapie in vitro et de comprendre le rôle de l'hypotonie dans ce modèle et son impact sur la mort des cellules cancéreuses.Nous avons déterminé les conditions optimales de traitement sur les cellules cancéreuses coliques humaines HCT116 à savoir une exposition des cellules pendant 30 minutes à 400µM d'oxaliplatine en conditions hypotoniques (G2.5%) à 37°C. Ces résultats ont été validés sur différentes lignées cancéreuses coliques humaines et murine. Nous avons également montré que ces conditions de traitements étaient également capables d’augmenter la cytotoxixité d’autres dérivés du platine comme le cisplatine et le carboplatine.La mort cellulaire induite par ce traitement en hypotonie est de type apoptotique, Et peut s’expliquer par une augmentation de l’incorporation intracellulaire d'oxaliplatine, en partie due à l'activation et à la trimérisation du transporteur du cuivre CTR1.Le traitement par l'oxaliplatine et le cisplatine (mais pas par le carboplatine) en hypotonie entraine également les stigmates de la mort immunogène, à savoir l'exposition de la calréticuline à la membrane, la libération d'ATP et le relargage d'HMGB1, suggérant que l'hypotonie permettrait d'entrainer la mort immunogène et une réponse du système immunitaire lors de cette modélisation de CIP.Enfin, in vivo nous avons pu mettre en évidence que le traitement de métastases intrapéritonéales de souris Balb/c par une injection intrapéritonéale d'oxaliplatine en hypotonie permettait un ralentissement de l’apparition de nodules tumoraux et une augmentation de la survie des souris.Ainsi, nous avons pu mettre en évidence dans ce travail que l'hypotonie est un des paramètres fondamentaux de la CIP et suggère que son utilisation pourrait permettre d'augmenter l’efficacité de la CIP et de prolonger la survie des patients. / IntraPeritoneal Chemotherapy (IPEC) is commonly used to treat colorectal cancer metastases. However there is no standardized protocol.The aim of this work was to model this chemotherapy in vitro and to understand the role of hypotonic conditions in this model and its impact on cell death.We determined that the optimal treatment parameters on HCT116 human colon cancer cells, were an exposure of the cells for 30 minutes to 400μM of oxaliplatin under hypotonic conditions (G2.5%) at 37 °C. These results have been validated on various human and murine colic cancer cell lines. We have also shown that these treatment conditions are also able to increase the cytotoxicity of other platinum derivatives such as cisplatin and carboplatin.The cell death induced by this treatment in hypotonia is apoptosis, and can be explained by an increase in the intracellular incorporation of oxaliplatin, partly due to the activation and trimerization of the CTR1 copper transporter.Treatment with oxaliplatin and cisplatin (but not carboplatin) in hypotonia also leads to the stigmata of immunogenic death, e.i. exposure of calreticulin at the membrane, release of ATP and HMGB1 in the supernatant, suggesting that hypotonia would entail immunogenic death and an immune system response during this IPEC modeling.Finally, we have been able to demonstrate in vivo that the treatment of intraperitoneal metastases of Balb/c mice by an intraperitoneal injection of oxaliplatin in hypotonia slowed down tumor nodules appearance and increased survival of the mice.Thus, in this work we highlighted that hypotonia is one of the fundamental parameters of IPEC which suggests that its use could make it possible to increase the efficacy of IPEC and maybe to prolong the survival of patients.

Peptidases regulate important physiological processes by controlling levels of bioactive peptides and occasionally through noncatalytic processes. This thesis presents a study of prolyl endopeptidase-like (PREPL), which is a peptidase involved in several human deletion syndromes, including hypotonia-cystinuria syndrome (HCS). Phenotypes tentatively attributed to PREPL deletion include hypotonia and decreased growth hormone (GH) levels. However, little is known about the mechanisms by which PREPL deletion causes these phenotypes. To better understand PREPL catalytic activity, we used an activity-based protein profiling fluorescence polarization screen to identify the first specific PREPL inhibitors. We proceeded to demonstrate the activity of these inhibitors in cells and discovered several classes of cell-active PREPL inhibitors. Further, one of these inhibitors, 1-isobutyl-3-oxo-3,5,6,7-tetrahydro-2H-cyclopenta[c]pyridine-4-carbonitrile, was able to enter mouse brains. To characterize PREPL substrate specificity, we performed several substrate profiling experiments, but no substrates could be identified, in line with reports from other groups who used related approaches to attempt to identify PREPL substrates. To characterize any noncatalytic functions of PREPL, we used an affinity purification-mass spectrometry approach (AP-MS) to search for any protein-protein interactions of PREPL. We identified brain-expressed X-linked 2 (BEX2) as a novel interactor of PREPL, and confirmed this interaction by immunoblot. Several other proteins identified in the AP-MS experiment, including several members of the STRIPAK complex are being further investigated for possible PREPL interaction. To determine whether HCS phenotypes are in fact due to PREPL deletion and to delineate the molecular pathways involved, we generated a conditional PREPL knockout mouse. These mice were visibly smaller than wildtypes and growth curve analysis verified that from week three of life, there was a significant difference in weight between wildtype and knockout mice. Initial surface righting task experiments also indicate that PREPL knockout pups may have a hypotonia phenotype. In summary, we have developed several new tools for studying PREPL catalytic and noncatalytic function, demonstrated that PREPL deletion causes a GH-related growth deficiency and possible hypotonia and thus moved several steps closer to understanding the molecular mechanisms underlying PREPL deletion phenotypes. / Chemistry and Chemical Biology

1 Abstract The subject of this thesis is hippotherapy as a supportive treatment method in children with Joubert syndrome and other hypotonic syndromes. In theoretical part is described Joubert syndrome in connection with education of students with special needs including legislation. In response to education of a child with disability there is further described therapy and basic therapeutic approaches that are often used concurrently with hippotherapy. Next part of thesis is focused on Joubert syndrome in terms of origin, causes, symptoms and diagnosis of the disease. With regards to research investigation in empiric part of the thesis there are further described specific educational approaches of individual with Joubert syndrome and other hypotonic syndromes. Theoretical part also comprises closer characteristics of hippotherapy as a possible supportive treatment method in terms of legislation, healthcare and social aspects. In empiric part there were used several methods of data collection within the qualitative research, these were analysis of studied literature, involved observation, case study, document analysis, narrative dialog with parent, discussion with hippotherapist and questionnaire submitted to parents of children attending hippotherapy. Key words: hippotherapy, Joubert syndrome, hypotonia,...

Introdução: As Distrofias Musculares Congênitas (DMCs) são um grupo clínica e geneticamente heterogêneo de doenças musculares que se manifestam ao nascimento ou no primeiro ano de vida, sendo caracterizadas por hipotonia, fraqueza muscular, retardo do desenvolvimento motor e retrações fibrotendíneas. O músculo esquelético apresenta-se distrófico, mas sem alterações estruturais específicas. Em quase metade dos casos a doença é causada pela deficiência da laminina alfa;-2 (merosina). Outras deficiências proteicas descritas incluem: colágeno VI, selenoproteína N1, várias glicosiltransferases responsáveis pela glicosilação da alfa- distroglicana e lamina A/C. Vários genes já foram identificados. Objetivo: o objetivo deste estudo foi a caracterização clínica, histológica e molecular das crianças com DMC por deficiência de lamina A/C. Método: Foram incluídos 13 pacientes com diagnóstico clínico e histológico de DMC, com expressão muscular normal para distrofina, sarcoglicanas, merosina, colágeno 6 e disferlina. Os pacientes foram reavaliados segundo protocolo clínico e neurológico. As biópsias musculares realizadas previamente foram revisadas e o estudo das mutações no gene da lamina A/C foi realizado através de sequenciamento de toda região codificadora do gene. Resultados: Identificamos mutações em 30,7% dos pacientes (quatro casos) com fenótipo clínico de DMC por deficiência de lamina A/C. Todas as mutações encontradas (p.E358K, p.R249W, e p.N39S) ocorreram em heterozigose e de novo e já haviam sido descritas na literatura em pacientes com distrofias musculares. Em geral, estes pacientes apresentavam um grave comprometimento motor com o característico aspecto de cabeça caída, com início dos sintomas nos primeiros dois anos de vida. A CPK estava elevada entre 2 a 6 vezes o padrão superior da normalidade. O padrão histológico variou desde um músculo levemente até gravemente distrófico. Curiosamente, no estudo histológico do músculo, um dos pacientes apresentou agregados intracitoplasmáticos. Um outro paciente apresentava associadamente alterações neurogênicas ao estudo eletroneuromiográfico. Em todos os casos observamos complicações respiratórias, cardíacas e distúrbios de deglutição. Houve um caso de morte súbita, provavelmente em decorrência de arritmia cardíaca. Conclusões: A correlação genótipo-fenótipo permanece difícil, mas todos os casos apresentaram sinal da cabeça caída, comprometimento respiratório, cardíaco e biópsia muscular distrófica. A ampliação do conhecimento clínico e histológico pode orientar o diagnóstico e direcionar para o estudo molecular adequado, além de permitir o diagnóstico precoce das complicações, tão frequentes na DMC por deficiência de lamina A/C. Os exons 1, 4 e 6 são os mais frequentemente mutados e devem ser pesquisados inicialmente. Esta série de casos contribui também por demonstrar a distribuição universal da doença / Background: The Congenital Muscular Dystrophies (CMD) are a clinically and genetically heterogeneous group of myopathies characterized by muscle hypotonia, delayed motor development and early onset of progressive muscle weakness with dystrophic pattern on muscle biopsy. The clinical course is broadly variable and can comprise the involvement of the brain and eyes. Almost half of the cases is caused by deficiency of laminin-alfa 2 (merosin). Other protein deficiencies described include: collagen VI, selenoprotein N1, several glycosyltransferases responsible for glycosylation of alfa-dystroglycan and lamin A/C. Several genes have been identified and the increased knowledge of new clinical and histological forms of CMD can guide diagnosis and direct appropriate molecular studies. LMNA-related CMD is often characterized by muscle weakness and a dropped head developed in the early years of life. Regarding lamin A/C deficiency, the immunohistochemical findings can be normal, probably because the protein change is functional only; this makes diagnosis using muscle samples more difficult. Objectives: The aim of this study was to characterize the clinical, histological and molecular aspects in patients with CMD related to deficiency of lamin A/C. Methods: thirteen children with clinical and histological diagnosis of CMD with normal muscle expression for dystrophin, merosin, collagen 6, sarcoglycans and dysferlin were included in this study. The LMNA gene was sequenced after amplification of all coding exons. In addition, the muscle biopsies were revised. Results: In 30.7% (four cases) of our patients with typical clinical phenotype of lamin A/C deficiency were detected mutations on LMNA gene and all of them presented dropped-head syndrome, restrictive ventilator insufficiency, cardiac changes, increased serum CPK level and myopathic/dystrophic aspect on muscle biopsy. Two of the patients had normal motor development milestones in the first months of life and subsequently developed cervical and limb weakness. The other two patients presented a more severe motor involvement and failure to walk. One patient showed associated peripheral neuropathy. Curiously one case had myofibrillar aggregates on muscle biopsy. All mutations (p.E358K, p.R249W and p.N39S) were heterozygous and de novo and had been previously described in patients with muscular dystrophy. Conclusion: Genotype/phenotype correlation in CMD remains difficult. However patients with LMNA mutation and CMD seems to have a more homogeneous phenotype characterized by dropped head, severe motor disability, and cardiac and pulmonary involvement. Mutations on exons 1, 4 and 6 should be tested first. This case series also contributes for showing the universal distribution of the disease

A síndrome de Prader-Willi é uma desordem complexa neurogenética associada a três mecanismos genéticos distintos: deleção paterna da região 15q11-q13, dissomia uniparental materna do cromossomo 15 e defeitos no centro de imprinting genômico. As principais características da síndrome na primeira fase são a hipotonia de causa desconhecida em neonatos, dismorfismos, dificuldades de alimentação e hipogonadismo. O principal objetivo deste trabalho foi identificar portadores da síndrome de Prader-Willi em neonatos (pacientes com até 28 dias de vida) que apresentaram hipotonia neonatal em maternidades de São Paulo. Neste estudo foram analisados por teste de metilação dois pacientes com suspeita da síndrome de Prader-Willi que apresentavam os requisitos de inclusão do trabalho. Para que o teste fosse feito de maneira menos invasiva possível foi realizada a coleta de saliva dos pacientes por swab de bochecha, para extração de DNA. Em um período de um ano, foi confirmada a síndrome em um paciente do grupo. Mesmo com um número amostral reduzido já esperado pelo curto período de coleta, foi diagnosticado um caso precocemente, o que reforça a importância da inclusão da pesquisa para a síndrome de Prader-Willi no grupo de neonatos hipotônicos de causa desconhecida. / Prader-Willi syndrome is a complex neurogenetic disorder associated with three distinct genetic mechanisms. They are: the 15q11-q13 paternal deletion, maternal uniparental disomy of chromosome 15 and defects in the imprinting center. The main characteristics of the syndrome in the first phase are the hypotonia of unknown cause in neonates, dysmorphisms, feeding difficulties and hypogonadism. The main objective of this study was to identify neonates with Prader-Willi syndrome (patients up to 28 days old) that presented neonatal hypotonia. Two hospitals, Hospital das Clínicas da Faculdade de Medicina da Universidade São Paulo and Hospital Maternidade Amador Aguiar, collaborate with this investigation. In this study, two patients with hypotonia and poor suck satisfied the diagnostic criteria and were analyzed by methylation test. In order to make the test less invasive, saliva was collected from patients by swab. During a period of one year, the syndrome was confirmed in one patient in the group. Even with a reduced sample, already expected due to the short collection period, a case was early diagnosed, which reinforces the importance of including the genetic tests for Prader-Willi syndrome in the group of hypotonic neonates of unknown cause.

Spinal muscular atrophy (SMA) is a hereditary disease characterized by progressive loss of -motoneurons of the spinal front corners, the consequence of which atrofizaci of muscles occurs. As a result, children become disabled and infirm dependent on the help and care of others at an early age. This is a relatively rare disease, the prevalence is about 1: 6,000 children. Spinal muscular atrophy is divided into 4 types according to its severity and time of onset of symptoms. Despite significant longtime research, it has failed to find a drug that could cure this disease so far. To the present date, there are only methods that slow the progression. The survey also contained 4 research questions, namely: What are the principles of treating a child with spinal muscular atrophy ? What are the most common problems in the care of a child with spinal muscular atrophy ? Are parents adequately educated on the issue of child with spinal muscular atrophy ? What impact has the presence of a child with spinal muscular atrophy in his family? Qualitative research was used in the implementation of the empirical part . Two qualitative methods were used to collect the data, a semi-structured interview and a hidden observation of the participant . Interviews were conducted with 3 research files, with 11 general nurses from the České Budejovice Hospital and University Hospital Motol, 7 mothers of children with I and II. type SMA of a summer camp for children with SMA and with 5 personal assistants. This thesis should help nurses and the public to gain awareness of the disease of Spinal Muscular Atrophy. It refers to all aspects of care of such a sick child, with which their parents daily struggle. Caring for a child with SMA is very difficult for their caregivers and requires considerable restrictions for the whole family. Information observed during the research were presented at a seminar for nurses in the České Budejovice Hospital in January 2015.

Introdução: As Distrofias Musculares Congênitas (DMCs) são um grupo clínica e geneticamente heterogêneo de doenças musculares que se manifestam ao nascimento ou no primeiro ano de vida, sendo caracterizadas por hipotonia, fraqueza muscular, retardo do desenvolvimento motor e retrações fibrotendíneas. O músculo esquelético apresenta-se distrófico, mas sem alterações estruturais específicas. Em quase metade dos casos a doença é causada pela deficiência da laminina alfa;-2 (merosina). Outras deficiências proteicas descritas incluem: colágeno VI, selenoproteína N1, várias glicosiltransferases responsáveis pela glicosilação da alfa- distroglicana e lamina A/C. Vários genes já foram identificados. Objetivo: o objetivo deste estudo foi a caracterização clínica, histológica e molecular das crianças com DMC por deficiência de lamina A/C. Método: Foram incluídos 13 pacientes com diagnóstico clínico e histológico de DMC, com expressão muscular normal para distrofina, sarcoglicanas, merosina, colágeno 6 e disferlina. Os pacientes foram reavaliados segundo protocolo clínico e neurológico. As biópsias musculares realizadas previamente foram revisadas e o estudo das mutações no gene da lamina A/C foi realizado através de sequenciamento de toda região codificadora do gene. Resultados: Identificamos mutações em 30,7% dos pacientes (quatro casos) com fenótipo clínico de DMC por deficiência de lamina A/C. Todas as mutações encontradas (p.E358K, p.R249W, e p.N39S) ocorreram em heterozigose e de novo e já haviam sido descritas na literatura em pacientes com distrofias musculares. Em geral, estes pacientes apresentavam um grave comprometimento motor com o característico aspecto de cabeça caída, com início dos sintomas nos primeiros dois anos de vida. A CPK estava elevada entre 2 a 6 vezes o padrão superior da normalidade. O padrão histológico variou desde um músculo levemente até gravemente distrófico. Curiosamente, no estudo histológico do músculo, um dos pacientes apresentou agregados intracitoplasmáticos. Um outro paciente apresentava associadamente alterações neurogênicas ao estudo eletroneuromiográfico. Em todos os casos observamos complicações respiratórias, cardíacas e distúrbios de deglutição. Houve um caso de morte súbita, provavelmente em decorrência de arritmia cardíaca. Conclusões: A correlação genótipo-fenótipo permanece difícil, mas todos os casos apresentaram sinal da cabeça caída, comprometimento respiratório, cardíaco e biópsia muscular distrófica. A ampliação do conhecimento clínico e histológico pode orientar o diagnóstico e direcionar para o estudo molecular adequado, além de permitir o diagnóstico precoce das complicações, tão frequentes na DMC por deficiência de lamina A/C. Os exons 1, 4 e 6 são os mais frequentemente mutados e devem ser pesquisados inicialmente. Esta série de casos contribui também por demonstrar a distribuição universal da doença / Background: The Congenital Muscular Dystrophies (CMD) are a clinically and genetically heterogeneous group of myopathies characterized by muscle hypotonia, delayed motor development and early onset of progressive muscle weakness with dystrophic pattern on muscle biopsy. The clinical course is broadly variable and can comprise the involvement of the brain and eyes. Almost half of the cases is caused by deficiency of laminin-alfa 2 (merosin). Other protein deficiencies described include: collagen VI, selenoprotein N1, several glycosyltransferases responsible for glycosylation of alfa-dystroglycan and lamin A/C. Several genes have been identified and the increased knowledge of new clinical and histological forms of CMD can guide diagnosis and direct appropriate molecular studies. LMNA-related CMD is often characterized by muscle weakness and a dropped head developed in the early years of life. Regarding lamin A/C deficiency, the immunohistochemical findings can be normal, probably because the protein change is functional only; this makes diagnosis using muscle samples more difficult. Objectives: The aim of this study was to characterize the clinical, histological and molecular aspects in patients with CMD related to deficiency of lamin A/C. Methods: thirteen children with clinical and histological diagnosis of CMD with normal muscle expression for dystrophin, merosin, collagen 6, sarcoglycans and dysferlin were included in this study. The LMNA gene was sequenced after amplification of all coding exons. In addition, the muscle biopsies were revised. Results: In 30.7% (four cases) of our patients with typical clinical phenotype of lamin A/C deficiency were detected mutations on LMNA gene and all of them presented dropped-head syndrome, restrictive ventilator insufficiency, cardiac changes, increased serum CPK level and myopathic/dystrophic aspect on muscle biopsy. Two of the patients had normal motor development milestones in the first months of life and subsequently developed cervical and limb weakness. The other two patients presented a more severe motor involvement and failure to walk. One patient showed associated peripheral neuropathy. Curiously one case had myofibrillar aggregates on muscle biopsy. All mutations (p.E358K, p.R249W and p.N39S) were heterozygous and de novo and had been previously described in patients with muscular dystrophy. Conclusion: Genotype/phenotype correlation in CMD remains difficult. However patients with LMNA mutation and CMD seems to have a more homogeneous phenotype characterized by dropped head, severe motor disability, and cardiac and pulmonary involvement. Mutations on exons 1, 4 and 6 should be tested first. This case series also contributes for showing the universal distribution of the disease

Orientadores: Cássio Luis Zannettini Riccetto, Simone Botelho Pereira / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-20T03:58:07Z (GMT). No. of bitstreams: 1 Lanza_AnaHelenaBarbosa_M.pdf: 1640627 bytes, checksum: c135a5857fcde47208c0a3c7f837045b (MD5) Previous issue date: 2011 / Resumo: Objetivo. Avaliar o efeito de um programa supervisionado de cinesioterapia sobre a contratilidade do assoalho pélvico, e sua eventual correlação com a função orgásmica feminina. Sujeito e Métodos. Para este estudo clínico, prospectivo, randomizado, controlado e cego, foram inclusas 20 mulheres, com média de idade de 26,6 ± 6,1 anos, com queixa de falta de orgasmo durante a atividade sexual, as quais foram divididas aleatoriamente em dois grupos. Grupo 1 (G1): 10 mulheres; avaliadas quanto à função orgásmica e quanto à contratilidade muscular do assoalho pélvico; realizaram um protocolo de exercícios cinesioterapêuticos (12 sessões individuais, com duração de 30 minutos, duas vezes por semana), focado no fortalecimento muscular pélvico; e reavaliada quanto à função orgásmica e quanto à contratilidade muscular; Grupo 2 (G2): 10 mulheres; avaliadas quanto à função orgásmica e quanto à contratilidade muscular do assoalho pélvico; não realizaram o protocolo de exercícios cinesioterapêuticos; foram reavaliadas quanto à função orgásmica e quanto à contratilidade muscular simultaneamente às mulheres do G1, sendo denominado G2-Controle. Após uma semana, esse grupo realizou o mesmo protocolo de exercícios cinesioterapêuticos, foi reavaliado quanto à função orgásmica e quanto à contratilidade muscular, sendo denominado G2-Tratado. A função orgásmica foi avaliada por meio do domínio orgasmo do questionário validado para língua portuguesa Female Sexual Function Index (FSFI), e por meio do cálculo do Coeficiente de Capacidade Orgásmica (CCO). As avaliações da contratilidade muscular do assoalho pélvico foram realizadas por segundo pesquisador, o qual não tinha conhecimento do programa de tratamento, através de palpação digital (PD) e de eletromiografia de superficie (EMGs - com sensor intravaginal), enquanto que, o programa de exercícios cinesioterapêuticos foi elaborado e supervisionado por pesquisador, o qual não participou das avaliações da contratilidade muscular do assoalho pélvico. O questionário International Consultation on Incontinence Questionnaire Short-Form, validado para a língua portuguesa, foi aplicado na avaliação inicial, no intuito de verificar a coexistência da incontinência urinária. Para análise estatística foram utilizados o Teste t de Student, o Teste de Correlação de Pearson, e o Teste Regressão Linear Simples, com nível de significância de 5%. Resultados. Em contraste com o grupo controle (G2-Controle), os grupos que realizaram o programa de exercícios cinesioterapêuticos proposto (G1 e G2-Tratado) apresentaram aumento significativo na contratilidade do assoalho pélvico, tanto a avaliada pela PD (p<0,001), quanto a mensurada pela EMGs (p<0,001), e este aumento de contratilidade se correlacionou de forma significativa com a melhora no escore do domínio orgasmo do FSFI (p<0,001), e no escore do Coeficiente de Capacidade Orgásmica (p=0,001). Conclusão. O programa de exercícios cinesioterapêuticos proposto promoveu aumento na contratilidade do assoalho pélvico, com concomitante melhora da função orgásmica, indicando que essa abordagem terapêutica possa ser adjuvante no tratamento da disfunção orgásmica feminina / Abstract: Objective. Evaluate the effect of a protocol supervised of the kinesiotherapy on the contractility of the pelvic floor, and its possible correlation with female orgasmic function. Subjects and methods. For this clinical, prospective, randomized, controlled, blind study, were included 20 women, mean age 26.6 ± 6.1 years, complaining of lack of orgasm during sexual activity, which were randomly divided into two groups. Group 1 (G1): 10 women, evaluated for orgasmic function and on the contractility of the pelvic floor, made a kinesiotherapy protocol (12 sessions, lasting 30 minutes, twice a week), focused on muscle strengthening, and reassessed as the orgasmic function and the contractility of the pelvic floor; Group 2 (G2): 10 women, evaluated for orgasmic function and on the contractility of the pelvic floor, did not realize the kinesiotherapy protocol, were reassessed on the orgasmic function and on the contractility of the pelvic floor while the women in the G1, and called G2- Control. After one week, this group received the same kinesiotherapy protocol, was reassessed as the orgasmic function and on the contractility of the pelvic floor, and called G2- Treaty. Orgasmic function was assessed using the orgasm domain of the validated questionnaire to portuguese Female Sexual Function Index (FSFI), and by calculating the Coefficient of Orgasmic Capacity (COC). The assessments of the pelvic floor muscle contractility were performed by the second researcher, which was not aware of the treatment program, by digital palpation (DP) and surface electromyography (sEMG - with intravaginal sensor), while kinesiotherapy program was drafted and supervised by a researcher no involved in the assessments of contractility of the pelvic floor. The International Consultation on Incontinence Questionnaire, validated for the portuguese language was used in the initial assessment, in order to verify the coexistence of urinary incontinence. Statistical analysis was performed using the Student t Test, the Pearson Correlation Test, and the Simple Linear Regression Test, with a significance level of 5%. Results. In contrast to the control group xvi (G2-control), groups that performed kinesiotherapy (G1 and G2-Treaty) showed a significant increase in contractility of the pelvic floor, assessed by PD (p <0,001), and measured by EMG (p <0.001), and this increase in contractility was positively correlated with the improvement in the orgasm domain score of the FSFI (p <0,001), and the score of the Coefficient Orgasmic Capacity (p = 0,001). Conclusion. The kinesiotherapy exercises program promoted increase in contractility of the pelvic floor, with concomitant improvement in orgasmic function, indicating that this therapeutic approach could be an adjunct in the treatment of female orgasmic dysfunction / Mestrado / Fisiopatologia Cirúrgica / Mestre em Ciências da Cirurgia